Status of Direct-acting Antiviral Therapy for HCV Infection and Remaining Challenges

Chronic infection with hepatitis C virus (HCV) is a major cause of liver disease and hepatocellular carcinoma worldwide. Following the discovery of HCV 3 decades ago, the identification of the structure of the viral proteins, combined with high-throughput replicon models, enabled the discovery and development of direct-acting antivirals. These agents have revolutionized care of patients, with cure rates of more than 90%. We review the status of direct-acting antiviral therapies for HCV infection and discuss remaining challenges.

Source: Gastroenterology - October 17, 2018 Category: Gastroenterology Authors: Thomas F. Baumert, Thomas Berg, Joseph K. Lim, David R. Nelson Source Type: research